TeenCove: A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Sponsor
ModernaTX, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04649151
Collaborator
Biomedical Advanced Research and Development Authority (U.S. Fed)
3,724
46
3
41.6
81
1.9

Study Details

Study Description

Brief Summary

The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the safety and reactogenicity of a single dose level of mRNA-1273 vaccine administered in 2 doses 28 days apart to an adolescent population. The study will also evaluate the safety of an optional mRNA-1273 single dose level booster dose (BD).

Condition or Disease Intervention/Treatment Phase
  • Biological: mRNA-1273
  • Biological: Placebo
Phase 2/Phase 3

Detailed Description

This is a Phase 2/3 study, with Part 1A (Blinded Phase), Part 1B (Open-label Observational Phase), Part 1C (Booster Dose (BD) Phase) which consists of Part 1C-1 and Part 1C-2 and Part 2 (Open-Label). Participants in Part 1A are blinded to their treatment assignment, with participants receiving either 2 active mRNA-1273 vaccine doses or placebo. Part 1B of the study is designed to offer participants whose age group becomes Emergency Use Authorization (EUA) eligible to be unblinded so that participants who received placebo in Part 1A can request 2 doses of open-label mRNA-1273 vaccine. Part 1C-1 of the study will offer participants in Part 1A and Part 1B who are at least 5 months from the last dose, the option to request a homologous BD of mRNA-1273. Part 1C-2 is designed to provide a heterologous BD of mRNA-1273 to eligible participants who completed primary COVID-19 vaccination series with a non-Moderna vaccine under EUA and are at least 3 months from the last dose. Part 2 is an open-label design. Participants will receive 2 doses of mRNA-1273 SARS-CoV-2 vaccine and a BD.

Please access http://TeenCoveStudy.com for additional information, such as Study Overview, Participation, Site Locations along with contact numbers for each location for the study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
3724 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Part 1A is observer-blind. Participants will remain blinded until the initiation of Part 1B or Part 1C or Part 2.
Primary Purpose:
Prevention
Official Title:
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of Age
Actual Study Start Date :
Dec 9, 2020
Anticipated Primary Completion Date :
May 28, 2024
Anticipated Study Completion Date :
May 28, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: mRNA-1273

Part 1A (Blinded Phase): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (100 microgram [ug] each), 28 days apart, on Day 1 and Day 29. Part 1B (Open-Label Phase): Participants who cross over from placebo in Part 1A to Part 1B will receive 2 IM injections of mRNA-1273 (100 ug each), 28 days apart on Open Label Day 1 and Open Label Day 29. Part 2 (Open-Label): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (50 ug each), 28 days apart, on Day 1 and Day 29.

Biological: mRNA-1273
Sterile liquid for injection

Placebo Comparator: Placebo

Part 1A (Blinded Phase): Participants will receive 2 IM injections of mRNA-1273 matching placebo, 28 days apart, on Day 1 and Day 29.

Biological: Placebo
0.9% sodium chloride (normal saline) injection

Experimental: mRNA-1273 BD

Part 1C-1 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, 5 months after the last dose of Part 1A and 1B. Part 1C-2 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, at least 3 months post-last dose. Part 2 (Open-Label): Participants will receive 1 IM injection as a BD of mRNA-1273 (50 ug) on Day 149, at least 3 months post-Dose 2.

Biological: mRNA-1273
Sterile liquid for injection

Outcome Measures

Primary Outcome Measures

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) [Up to Day 8 (7 days post-vaccination)]

  2. Number of Participants with Unsolicited Adverse Events (AEs) [Up to Day 29 (28 days post-vaccination)]

  3. Number of Participants with Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), or Adverse Events of Special Interest (AESI) [Up to Day 514]

  4. Number of Participants With Serum Antibody (Ab) Levels that Meet or Exceed the Threshold of Protection From COVID-19 [Day 57 (28 days after second dose)]

    Acceptable serum Ab threshold as predefined for the study.

  5. Geometric Mean (GM) of the Serum Ab Level [Day 57 (28 days after second dose)]

  6. Seroresponse Rate (SRR) of Vaccine Recipients [Day 57 (28 days after second dose)]

  7. Number of Participants with AEs Leading to the Discontinuation From Study Post BD [Up to Day 514]

  8. GM of the Serum Ab Level of Original Strain Post BD [BD-Day 29]

  9. SRR of Vaccine Recipients of Original Strain Post BD [BD-Day 29]

Secondary Outcome Measures

  1. GM of SARS-CoV-2 Spike Protein (S2P)-Specific Binding Antibody (bAb) [Day 1, Day 57 (1 month after dose 2), Day 209 (6 months after dose 2), and Day 394 (1 year after dose 2)]

  2. GM of SARS-CoV-2-Specific Neutralizing Antibody (nAb) [Day 1, Day 57 (1 month after dose 2), Day 209 (6 months after dose 2), and Day 394 (1 year after dose 2)]

  3. Number of Participants with a SARS-CoV-2 Infection (Symptomatic or Asymptomatic) Starting 14 Days after the Second Dose of mRNA-1273 or Placebo [Day 43 up to Day 394]

    Clinical signs indicative of SARS-CoV-2 infection as predefined for the study.

  4. Number of Participants With Asymptomatic SARS-CoV-2 Infection Measured by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and/or bAb Levels Against SARS-CoV-2 Nucleocapsid Protein [Day 43 up to Day 394]

  5. Number of Participants with a First Occurrence of Symptomatic COVID-19 Starting 14 days After Second Dose of mRNA-1273 or Placebo [Day 43 up to Day 394]

    Clinical signs indicative of symptomatic COVID-19 as predefined for the study.

  6. GM of the Serum Ab Level of Circulating Strain [BD-Day 29; Part 2: Day 57]

  7. SRR of Vaccine Recipients of Circulating Strain [BD-Day 29; Part 2: Day 57]

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
For Part 1A and Part 2:
  • Participants 12 to <18 years of age at the time of consent (Screening Visit, Day 0) who, in the opinion of the Investigator, are in good general health based on review of medical history and screening physical examination.

  • Investigator assessment that the participant, in the case of an emancipated minor, or parent(s)/legally acceptable representative(s) [LAR(s)] understand and is willing and physically able to comply with protocol-mandated follow up, including all procedures and provides written informed consent/assent.

  • Body mass index (BMI) at or above the third percentile according to World Health Organization (WHO) Child Growth Standards at the Screening Visit (Day 0)

  • Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as premenarche or surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy).

  • Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test at Screening (Day 0), on the day of the first injection (Day 1), on the day of the second injection (Day 29), and on the day of the BD (Day 149) in Part 2; has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (Day 1); and has agreed to continue adequate contraception through 3 months following the second injection (Day 29) and BD (Day 149) in Part 2.

For Part 1C-1 Homologous Booster Dose:
  • Participants must have been previously enrolled in the mRNA-1273-P203 study, are actively participating in Part 1A or Part 1B and are least 5 months from the last dose.

  • Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of the first injection (BD-Day 1).

Part 1C-2 Heterologous Booster Dose:
  • Male or female, 12 to < 18 years of age at the time of consent who, in the opinion of the investigator, is in good general health based on review of medical history and screening physical examination AND has completed non-Moderna primary COVID-19 vaccination series under EUA (for example, Pfizer) at least 3 months from consent.
Exclusion Criteria:
For Part 1A and Part 2:
  • Has a known history of SARS-CoV-2 infection within 2 weeks prior to administration of investigational product (IP) or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection of COVID-19 within 2 weeks prior to administration of IP (Part 2 participants only).

  • Travel outside of the United States or home country (Part 2 only) in the 28 days prior to the Screening Visit (Day 0).

  • Pregnant or breastfeeding

  • Is acutely ill or febrile 24 hours prior to or at the Screening Visit (Day 0). Fever is defined as a body temperature ≥38.0°Celsius (C)/≥100.4°Farenheit (F). Participants who meet this criterion may have visits rescheduled within the relevant study visit windows. Afebrile participants with minor illnesses can be enrolled at the discretion of the Investigator.

  • Prior administration of an investigational coronavirus (for example, SARS-CoV, Middle East Respiratory Syndrome [MERS-CoV]) vaccine

  • Current treatment with investigational agents for prophylaxis against COVID-19

  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the Investigator's judgment

  • Current use of any inhaled substance (for example, tobacco or cannabis smoke, nicotine vapors)

  • History of chronic smoking (≥1 cigarette a day) within 1 year of the Screening Visit (Day 0)

  • History of illegal substance use or alcohol abuse within the past 2 years. This exclusion does not apply to historical cannabis use that was formerly illegal in the participant's state but is legal at the time of screening.

  • History of a diagnosis or condition that, in the judgment of the Investigator, may affect study endpoint assessment or compromise participant safety, specifically:

  • Congenital or acquired immunodeficiency, including human immunodeficiency virus (HIV) infection

  • Suspected active hepatitis

  • Has a bleeding disorder that is considered a contraindication to IM injection or phlebotomy

  • Dermatologic conditions that could affect local solicited AR assessments

  • History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine

  • Diagnosis of malignancy within the previous 10 years (excluding nonmelanoma skin cancer)

  • Febrile seizures

  • Receipt of:

  • Any licensed vaccine within 28 days before the first dose (Day 1) or plans for receipt of any licensed vaccine through 28 days following any study injection

  • Systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥20 mg/day prednisone equivalent). Topical tacrolimus is allowed if not used within 14 days prior to the day of enrollment. Participants may have visits rescheduled for enrollment if they no longer meet this criterion within the Screening Visit window. Inhaled, nasal, and topical steroids are allowed.

  • Intravenous blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment

  • Has donated ≥450 mL of blood products within 28 days prior to the Screening Visit (Day

  1. or plans to donate blood products during the study
  • Participated in an interventional clinical study within 28 days prior to the Screening Visit (Day 0) or plans to do so while participating in this study

  • Is an immediate family member or has a household contact who is an employee of the research center or otherwise involved with the conduct of the study

  • History of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically:

  • Congenital or acquired immunodeficiency, including human immunodeficiencyvirus (HIV) infection.

  • Suspected active hepatitis

  • Has a bleeding disorder that is considered a contraindication to IM injection orphlebotomy

  • Dermatologic conditions that could affect local solicited AR assessments

  • History of anaphylaxis, urticaria, or other significant AR requiring medicalintervention after receipt of a vaccine

  • Diagnosis of malignancy within the previous 10 years (excluding nonmelanomaskin cancer)

  • Febrile seizures

For Part 1B:
  • Participants who were previously enrolled in the mRNA-1273 P203 study and chose to be unblinded.

  • Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of the first injection (Open-Label-Day 1) and on the day of the second injection (Open-Label-Day 29).

For Part 1C-1 and Part 1C-2:
  • Pregnant or breastfeeding.

  • Is acutely ill or febrile 24 hours prior to or at the Screening Visit (Day 0). Fever is defined as a body temperature ≥ 38.0°C/≥ 100.4°F. Participants who meet this criterion may have visits rescheduled within the relevant study visit windows. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.

  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.

  • History of a diagnosis or condition (after enrolment in Part 1A for potential participants in Part 1C-1) that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety:

  • Suspected active hepatitis

  • Has a bleeding disorder that is considered a contraindication to IM injection or phlebotomy

  • Dermatologic conditions that could affect local solicited AR assessments

  • History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine

  • Diagnosis of malignancy (excluding nonmelanoma skin cancer)

  • Receipt of:

• Any authorized or licensed vaccine within 28 days before the first dose of investigational product (IP) or plans (COVID-19 vaccines are not exclusionary) for receipt of any licensed vaccine through 28 days following the last dose of IP or any seasonal influenza vaccine within 14 days before the first dose of IP or plans for receipt of any seasonal influenza vaccine 14 days following the last dose of IP.

  • Participated in an interventional clinical study, other than mRNA-1273-P203 study, within 28 days prior to the Screening Visit (BD-Day 0) or plans to do so while participating in this study.

  • History of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically:

  • Congenital or acquired immunodeficiency, including human immunodeficiencyvirus (HIV) infection.

  • Suspected active hepatitis

  • Has a bleeding disorder that is considered a contraindication to IM injection orphlebotomy

  • Dermatologic conditions that could affect local solicited AR assessments

  • History of anaphylaxis, urticaria, or other significant AR requiring medicalintervention after receipt of a vaccine

  • Diagnosis of malignancy within the previous 10 years (excluding nonmelanomaskin cancer)

  • Febrile seizures

Part 1C-2 Heterologous Booster Dose:
  • Has a known history of SARS-CoV-2 infection within 2 weeks prior to administration of IP or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection or COVID 19 within 2 weeks prior to administration of IP.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Velocity Clinical Research - Banning Banning California United States 92220
2 Altus Research - Hunt - PPDS Palm Springs Florida United States 45242
3 Meridian Clinical Research - (Macon Georgia) - Platinum - PPDS Macon Georgia United States 01605
4 Wee Care Pediatrics Macon Georgia United States 31201
5 Alliance for Multispecialty Research, LLC Roswell Georgia United States 30076
6 IACT Health - Roswell - IACT - HyperCore - PPDS Roswell Georgia United States 75024
7 Clinical Research Atlanta Stockbridge Georgia United States 30281
8 Clinical Research Prime - ClinEdge - PPDS Idaho Falls Idaho United States 83404
9 San Marcus Research Clinic Inc Idaho Falls Idaho United States 83404
10 Velocity Clinical Research - Valparaiso Valparaiso Indiana United States 46383
11 Wee Care Pediatrics - Roy El Dorado Kansas United States 67042
12 Alliance for Multispecialty Research -El Dorado El Dorado Kansas United States 68114
13 Meridian Clinical Research (Sioux City - Iowa) Louisville Kentucky United States 40223
14 Medpharmics - Metairie Metairie Louisiana United States 70006
15 Medpharmics - Gulfport Gulfport Mississippi United States 39503
16 Sundance Clinical Research - Platinum - PPDS Saint Louis Missouri United States 78705
17 Meridian Clinical Research (Hastings-Nebraska) - Platinum - PPDS Hastings Nebraska United States 33461
18 Cottonwood Pediatrics Hastings Nebraska United States 68901
19 Quality Clinical Research - HyperCore - PPDS Omaha Nebraska United States 30341
20 IACT Health - Roswell - IACT - HyperCore - PPDS Omaha Nebraska United States 68114
21 Olivo Medical and Wellness Center Omaha Nebraska United States 68134
22 Meridian Clinical Research (Omaha-Nebraska) - Platinum - PPDS Omaha Nebraska United States 84405
23 Medpharmics - Albuquerque Albuquerque New Mexico United States 87102
24 Child Healthcare Associates - East Syracuse East Syracuse New York United States 13057
25 Meridian Clinical Research (Endwell-New York) - Platinum - PPDS Endwell New York United States 13901
26 Premier Research Associate-Miami Endwell New York United States 13901
27 Vital Prospects Clinical Research Institute PC - CRN - PPDS Tulsa Oklahoma United States 68134
28 Cope Family Medicine - Ogden Clinic - CCT Tulsa Oklahoma United States 74136
29 Cyn3rgy Research - ClinEdge - PPDS Gresham Oregon United States 97030
30 Del Pilar Medical and Urgent Care Gresham Oregon United States 97030
31 Coastal Pediatric Associates Charleston South Carolina United States 29414
32 Meridian Clinical Research - Charleston, SC Charleston South Carolina United States 32829
33 Coastal Carolina Research Center North Charleston South Carolina United States 66219
34 Benchmark Research Austin Texas United States 78705
35 Crossroads Clinical Research Corpus Christi Texas United States 78413
36 DM Clinical Research - Kool Kids Pediatrics - ERN - PPDS Houston Texas United States 77065
37 ACRC Trials Plano Texas United States 75024
38 1st Care Medical Clinic - Phoenix San Antonio Texas United States 78229
39 Clinical Trials of Texas, Inc. - PPDS San Antonio Texas United States 78229
40 Tekton Research San Antonio Texas United States 78229
41 Tekton Research San Antonio Texas United States 78244
42 South Ogden Family Medicine/Ogden Clinic - CCT Research South Ogden Utah United States 30281
43 Advanced Clinical Research - Jordan Valley - ERN - PPDS West Jordan Utah United States 84088
44 Wee Care Pediatrics - Kaysville Norfolk Virginia United States 23502
45 Meridian Clinical Research (Norfolk, Virginia) Norfolk Virginia United States 74136
46 Meridian Clinical Research - Family Practice Ports - Portsmouth - Platinum - PPDS Portsmouth Virginia United States 39503

Sponsors and Collaborators

  • ModernaTX, Inc.
  • Biomedical Advanced Research and Development Authority

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
ModernaTX, Inc.
ClinicalTrials.gov Identifier:
NCT04649151
Other Study ID Numbers:
  • mRNA-1273-P203
First Posted:
Dec 2, 2020
Last Update Posted:
Apr 4, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by ModernaTX, Inc.

Study Results

No Results Posted as of Apr 4, 2022